EFFICACY AND SAFETY OF UPADACITINIB AFTER 2 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)

Remo Panaccione  1     Peter D. R. Higgins  2     Gary Lichtenstein  3     Hiroshi Nakase  4     Michelle Kujawski  5     Erica Cheng  5     Dapo Ilo  5     Gweneth Levy  5     Jason Eccleston  5     Sarah C. Glover  6     Silvio Danese  7     Jean-Frédéric Colombel  8     Stefan Schreiber  9    
1 University of Calgary, Calgary, Canada
2 Division of Gastroenterology, University of Michigan, Ann Arbor, United Kingdom
3 University of Pennsylvania School of Medicine, Merion Station, United States
4 Sapporo Medical University School of Medicine, Sapporo, Japan
5 AbbVie, Inc, North Chicago, United States
6 University of Mississippi Medical Center (UMMC), Jackson, United States
7 Humanitas University and Humanitas Research Hospital, IRCCS, Milan, Italy
8 Icahn School of Medicine at Mount Sinai, New York, United States
9 University Hospital Schleswig-Holstein, Kiel, Germany

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing